血清TNFAIP8、HE4及FSH在卵巢癌中的意义及相关性研究

摘要/Abstract

摘要： 目的探究血清肿瘤坏死因子-α诱导蛋白8（Tumor Necrosis Factor-α Inducing Protein 8,TNFAIP 8）、人附睾蛋白-4（Human Epididymal Protein-4,HE4）、卵泡刺激素（Follicle Stimulating Hormone,FSH）在卵巢癌中的表达意义,并分析上述指标相关性及在卵巢癌诊断中的意义。方法选择2019年8月—2022年10月于聊城市传染病医院确诊为卵巢癌的88例患者为研究组,另取同期于聊城市传染病医院确诊为良性卵巢病变的50例患者为对照组,对比两组患者血清TNFAIP8、HE4及FSH水平差异,按照病理检测结果将研究组患者进行FIGO分期,并对比不同分期卵巢癌患者血清TNFAIP 8、HE4及FSH水平差异,采用Pearson相关性分析探究卵巢癌患者血清TNFAIP8、HE4及FSH相关性,并通过绘制ROC曲线的方式,计算血清TNFAIP 8、HE4及FSH对卵巢癌的诊断效能。结果研究组患者血清TNFAIP 8、HE4及FSH水平均明显高于对照组,差异有统计学意义（P<0.05）;按照病理检测结果将研究组患者分为Ⅰ+Ⅱ期亚组和Ⅲ+Ⅳ期亚组,对比显示Ⅲ+Ⅳ期亚组患者血清TNFAIP8、HE4及FSH水平均显著高于Ⅰ+Ⅱ期亚组,差异有统计学意义（P<0.05）;Pearson相关性分析显示,卵巢癌患者血清TNFAIP8水平与其HE4、FSH水平呈现正相关关系（r=0.221,P<0.05;r=0.594,P<0.05）,HE4水平与其FSH水平呈现正相关关系（r=0.163,P<0.05）;分别绘制血清TNFAIP 8、HE4及FSH水平鉴别卵巢癌ROC曲线,计算其AUC分别为0.924（95%CI：0.969~0.979,P<0.05）、0.909（95%CI：0.850~0.967,P<0.05）、0.757（95%CI：0.659~0.856,P<0.05）。结论卵巢癌患者血清TNFAIP8、HE4及FSH水平会出现异常升高表现,且与患者的病理分期可能存在相关性,可以考虑将上述因子应用于卵巢癌的鉴别诊断中。

关键词: 卵巢癌, 肿瘤坏死因子α诱导蛋白8, 人附睾蛋白-4, 卵泡刺激素, 诊断效能

Abstract: Objection To explore the expression significance of serum tumor necrosis factor-α inducing protein 8 (TNFAIP8), human epididymal protein-4 (HE4), and follicle stimulating hormone (FSH) in ovarian cancer, and the correlation between the above indicators and their significance in the diagnosis of ovarian cancer. Methods 88 patients diagnosed with ovarian cancer in our hospital from August 2019 to October 2022 were selected as the study group, and 50 patients diagnosed with benign ovarian lesions in our hospital during the same period were selected as the case control group. The differences in serum TNFAIP 8, HE4, and FSH between the two groups were compared. According to the pathological examination results, the study group patients were classified into FIGO stages, and the differences in serum TNFAIP 8, HE4, and FSH levels among ovarian cancer patients at different stages were compared, Using Pearson correlation analysis to explore the correlation between serum TNFAIP8, HE4, and FSH in ovarian cancer patients, and calculating the diagnostic efficacy of serum TNFAIP8, HE4, and FSH in ovarian cancer by plotting ROC curves. Results The serum levels of TNFAIP8, HE4, and FSH in the study group were significantly higher than those in the control group (P<0.05). According to the pathological examination results, the study group patients were divided into Ⅰ+Ⅱ subgroup and Ⅲ+Ⅳ subgroup. The comparison showed that the serum levels of TNFAIP 8, HE4, and FSH in the Ⅲ+Ⅳ subgroup patients were significantly higher than those in the Ⅰ+Ⅱ subgroup patients (P<0.05). Pearson correlation analysis showed that serum TNFAIP8 levels in ovarian cancer patients were positively correlated with their HE4 and FSH levels (r=0.221, P<0.05;r=0.594, P<0.05), while HE4 levels were positively correlated with their FSH levels (r=0.163, P<0.05). Draw serum TNFAIP8, HE4, and FSH levels to differentiate ovarian cancer ROC curves, and calculate their AUC as 0.924 (95%CI=0.969~0.979, P<0.05), 0.909 (95% CI=0.850~0.967, P<0.05), and 0.757 (95%CI=0.659~0.856,P<0.05), respectively. Conclusion The serum TNFAIP8, HE4 and FSH levels will show abnormal elevated manifestations, and they may be related to the pathological stage of patients, so the above factors can be considered in the differential diagnosis of ovarian cancer.

Key words: ovarian cancer, tumor necrosis factor-α inducing protein 8, human epididymal protein-4, follicle stimulating hormone, diagnostic effectiveness

中图分类号:

R711

黄磊, 张桂华. 血清TNFAIP8、HE4及FSH在卵巢癌中的意义及相关性研究[J]. 中华养生保健, 2024, 42(3): 15-18.

HUANG Lei, ZHANG Gui-hua. The Significance and Correlation of Serum TNFAIP8, HE4, and FSH in Ovarian Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(3): 15-18.

参考文献

[1] 孙丽丽,朱慧敏,庞丽娟,等.磷酸化AKT在卵巢癌中表达的临床意义及其与新癌基因REDD1表达的相关性研究[J].安徽医科大学学报,2014,49(12):1766-1770.
[2] 姚丽萍,袁浩冉,刘玉琴.2018年甘肃省肿瘤登记地区卵巢癌流行特征及2010—2018年变化趋势分析[J].中国肿瘤,2022,31(7):549-555.
[3] 敬源. 人附睾蛋白4、CA125和卵巢恶性风险预测模型与卵巢癌中的诊断、临床病理及分期的相关性研究[J].临床和实验医学杂志,2017,16(6):546-549.
[4] 王宇熙,郑建华,张广美,等.血清高迁移率蛋白A1与人附睾分泌蛋白4、CA125联合检测上皮性卵巢癌的临床价值[J].中国实用妇科与产科杂志,2013,29(9):741-744.
[5] 李莉,侯志敏.卵巢癌组织中miR-125B-5p通过调控己糖激酶-2降低肿瘤能量代谢和抑制肿瘤细胞增殖[J].癌症,2021,40(9):394-403.
[6] 黄雪梅,赵咏梅,蒲泽晏,等.血清CA125、HE4及MMP-9联合检测在卵巢癌早期诊断中的临床价值研究[J].标记免疫分析与临床,2016,23(9):1029-1032.
[7] 顾正忠,孙鹏达,王志成,等.肿瘤坏死因子-α诱导蛋白8样蛋白家族对炎症和肿瘤的调控作用及其机制研究进展[J].癌症进展,2020,18(19):1979-1983,2040.
[8] SALIMA S, RACHMAWATI A, HARSONO A B, et al.Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer[J]. Asian Pac J Cancer Prev,2022,23(8):2643-2647.
[9] 张莉,孙倩,张铭,等.川芎嗪对糖尿病患者体内及体外单核细胞肿瘤坏死因子-α-诱导蛋白-8-2、肿瘤坏死因子-α、组织因子表达水平影响[J].临床军医杂志,2021,49(2):145-147.
[10] 李洁,张昀,南鹏飞,等.腹水液基细胞学特征结合血清CA-125、HE4及影像学表现对诊断卵巢癌的意义[J].诊断病理学杂志,2021,28(7):532-535.
[11] 杨霄彦,郝春光,张志坚.孕激素通过HOXA9对人卵巢癌细胞增殖和迁移的机制研究[J].昆明医科大学学报,2022,43(10):35-42.
[12] 李向荣,杜旋,杨娟.血清CA199、CA125、HE4联合检测在卵巢癌诊断中的应用价值[J].实用癌症杂志,2020,35(6):1015-1018.
[13] 庄慧宇,娄彤,路军丽,等.HDAC3通过调控HE4表达增强上皮性卵巢恶性肿瘤增殖侵袭和迁移能力[J].现代妇产科进展,2020,29(7):493-498.
[14] 黄海琴,张广辉,张晓丽.TNFAIP8和TNFAIP2在乳腺肿瘤中的表达及临床意义[J].河北北方学院学报(自然科学版),2015,31(4):68-70.
[15] 李倩,王金辉.糖类抗原199人绒毛膜促性腺激素β及抗苗勒管激素对子宫内膜异位症并发卵巢癌的预测效能[J].中国妇幼保健,2022,37(11):1979-1981.
[16] 宋晓翠,滕洪涛,张建海,等.联合检测血清HE4和CA125在卵巢癌早期诊断及病情监测中的价值[J].实用医学杂志,2012,28(14):2380-2382.
[17] 付立业,田昕,李妍,等.血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者围手术期的变化及临床意义[J].现代肿瘤医学,2017,25(20):3295-3298.
[18] 朱攀,马瑞,雷蜜.上皮性卵巢癌患者中血清CA125、HE4、SMRP及细胞因子IL-8、IL-17联合检测意义分析[J].海南医学院学报,2017,23(8):1120-1123.
[19] 张安能,杨慧健,孙宏超.E-cadherin、CA199及HE4在子宫内膜异位症患者血清中的表达及与自身抗体的相关性[J].中国医药导刊,2021,23(9):647-652.